We had been hollering for an update - so we got one.

Not entirely fluff, though I think.

Instead of the general promise of partner-interest, he actually revealed a little about the intended structure, which makes it seem more likely that there is a known partner, or at least a few genuine candidates.

We knew there was break-through designation, but he confirmed for us that they have been meetings as recently as June 2 with the FDA, and that plans to more foreward with BETonMACE2 were moving.

He allayed at least SOME of our concerns about that big drop with his hedge fund explanation.

He confirmed pre-clinical trial progress for COVID, and status of PAH.

He did not say anything about dementia - I wonder whether they decided that was an artifact or whether they still plan to look at it.

He seemed to confirm that RVX will continue despite the books - for long enough to get to al this.

Lots of it is redundant, but we asked for an update. He wasnt likely to add immortality to the list of indications, or a 60 billion $ sale, after a few months mainly at home.

I call it "good enough" for what it was.